CARB-X Injects up to $48 Million to Accelerate First Portfolio

CARB-X

CARB-X Injects up to $48 Million to Accelerate First Portfolio 

BARDA, NIAID, Wellcome Trust and CARB-X took a bold step in strengthening the antibiotic pipeline by investing in 11 biotech companies that are developing new, life-saving antibacterial drugs and diagnostic products aimed at treating infections caused by antibiotic-resistant bacteria. Learn More >>

CARB-X INJECTS UP TO $48 MILLION TO ACCELERATE FIRST POWERED BY CARB-X PORTFOLIO OF DRUG DISCOVERY AND DEVELOPMENT PROJECTS TO TACKLE ANTIBIOTIC RESISTANCE

3 POTENTIAL NEW CLASSES OF ANTIBIOTICS, 4 INNOVATIVE NON-TRADITIONAL PRODUCTS AND 7 NEW MOLECULAR TARGETS AGAINST THE MOST URGENT DEADLIEST 'SUPERBUGS'